News and Insights
The latest news and insights from Genoa Healthcare.
- Behavioral Health
- Clinical Insights
- Treatment
Currently available and emerging therapy options for treatment-resistant depression
Studies show that 50% of people with major depressive disorder don’t respond adequately to initial antidepressant treatment.1 Additionally, an estimated 30% of people with major depressive disorder (MDD) experience treatment-resistant...
- Feb 24th, 2025
- Clinical Insights
- Treatment
RELEXXII®: 6 things to know about the new FDA-approved treatment for ADHD
Staying on top of new medication options for your consumers living with ADHD can be difficult. Learn more about the new FDA-approved medication RELEXXII®, a long-acting formulation of methylphenidate. 1....
- Feb 11th, 2025
- Behavioral Health
- Clinical Insights
- Treatment
4 things to know about Spravato® (Intranasal esketamine)
On January 21, 2025, the FDA approved Spravato® nasal spray as the first and only monotherapy for adults living with TRD. The new label expansion will offer greater flexibility in...
- Jan 28th, 2025
- Behavioral Health
- Clinical Insights
- Treatment
Esketamine: Latest research offers new hope for adolescents with treatment-resistant depression
Adolescents with treatment-resistant depression (TRD) often struggle with a lack of effective treatment options. While ketamine has been shown to help improve outcomes for adults living with major depressive disorder...
- Jan 24th, 2025
- Behavioral Health
- Clinical Insights
- Treatment
Brixadi®: 3 things to know about the buprenorphine treatment option
Staying on top of new medication therapy options for your consumers living with opioid use disorder (OUD) can be difficult. Learn how the new FDA-approved medication, Brixadi®, can help support...
- Oct 30th, 2024
- Behavioral Health
- Clinical Insights
- Treatment
Drug trends in behavioral health: What you need to know
Genoa Healthcare recently hosted a webinar where Pharmaceutical Program Manager Allie Butler, PharmD, and Clinical Pharmacist Cameron Yenney, PharmD, discussed the latest drug trends in behavioral health. Watch the recording...
- Oct 11th, 2024
- Behavioral Health
- Clinical Insights
- Treatment
Cobenfy™: 5 things to know about the new schizophrenia treatment option
Staying on top of new medication therapy options for your consumers living with schizophrenia can be difficult. Learn how the new FDA-approved medication, Cobenfy – approved on September 26, 2024...
- Oct 1st, 2024
- Clinical Insights
- HIV
- Treatment
Pharmacist-prescribed PrEP and PEP pilot expands pharmacy scope of practice
By Jennifer Finocchiaro, PharmD, AAHIVE The role of the pharmacist has changed significantly over the years, expanding from medication dispensing and counseling to providing direct patient care. As the pharmacy...
- Sep 10th, 2024
- Behavioral Health
- Clinical Insights
- Treatment
Understanding Tardive Dyskinesia: What you need to know
Tardive Dyskinesia (TD) – a neurological disorder associated with prolonged use of antipsychotic medications – affects over 600,000 people annually. Wondering what this means for the people you serve? Genoa...
- Apr 11th, 2024
- Behavioral Health
- Clinical Insights
- Treatment
March 2024 drug trend report
Staying on top of new drug launches and shortages can be difficult. Read Genoa Healthcare’s latest drug trend report for an overview and connect with your local pharmacy team to...
- Mar 13th, 2024